Bergen, Norway, 27 March 2024 – Reference is made to the stock exchange announcement from BerGenBio ASA (the “Company”) dated 14 June 2023 regarding the final results of the rights issue of 2,500,000,000 new shares in the Company (the “Offer Shares”), raising gross proceeds of NOK 250 million (the “Rights Issue”), and the allocation and … Read more
BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to proceed without study modification Bergen, Norway, March 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study … Read more
BERGEN, Norway, March 4, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will present at Carnegie’s 27th Annual Nordic Healthcare Seminar to be held on March 5th – 6th, 2024 in Stockholm, Sweden. The presentation will be … Read more
Bergen 19 February 2024 – Reference is made to the stock exchange announcement on 7 December 2023 regarding the approval and publication of a prospectus prepared by BerGenBio ASA (the “Company”) for the listing of new shares to be issued by the Company (the “Prospectus”). The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today … Read more
Bergen (Norway), February 14, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended December 31, 2023, and provided a business update. Highlights, including post period Phase 1b part of BGBC016 (1L NSCLC STK11m) progressed as … Read more
Bergen (Norge), 14. februar 2024 – BerGenBio ASA (OSE: BGBIO) er et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive AXL-kinasehemmere for alvorlige udekkede medisinske behov. Selskapet la i dag frem økonomiske resultater for kvartalet som ble avsluttet 31. desember 2023, og ga oppdateringer på driften. Viktigste hendelser i perioden, inkludert tiden etter kvartalsslutt … Read more
Bergen, Norway, February 7, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented “Investigating the effects of AXL inhibition during respiratory viral infections” during the 6th Forum on Respiratory Infections … Read more
Bergen, Norway, 6 February 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the fourth quarter 2023 on Wednesday 14 February 2024. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast … Read more
BERGEN, Norway, December 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to … Read more
Bergen, Norway, December 12, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 14th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 14, 2023, at 12:35pm … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.